(EQRX) $1.70 / 2 Cancer drugs awaiting approval in Europe with potential first approval in 2H of this year / Market cap $845 m trading massive below the cash balance of $1.4 billion ...Alphabet (Google) , Softbank , Blackrock and Vanguard alone holding over 100 million shares who paid around $10 per share ...
Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC
Sugemalimab: MAAs accepted for review by MHRA and EMA for the first-line treatment of metastatic NSCLC in combination with chemotherapy
Ended 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate runway into 2028
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.